«BioEq» recruits for patients with nonresectable or metastatic melanoma to participate in a phase II clinical study.
Study
medication: monoclonal
anti-PD-1 antibody.
Clinical
study length: Maximum 69 weeks, including screening (up to 4 weeks), clinical
study therapy (up to 53 weeks), further monitoring (up to 12 weeks)
We
invite adult male and female patients with:
- Histological verificate nonresectable or metastatic melanoma
- Elementary educed frequent or metastatic melanoma
- Disease progression after previous system therapy
Please contact us at 8-812-945-22-32 to learn more.